Country: Ամերիկայի Միացյալ Նահանգներ
language: անգլերեն
source: NLM (National Library of Medicine)
FLUCONAZOLE (UNII: 8VZV102JFY) (FLUCONAZOLE - UNII:8VZV102JFY)
Blenheim Pharmacal, Inc.
FLUCONAZOLE
FLUCONAZOLE 200 mg
ORAL
PRESCRIPTION DRUG
Fluconazole is indicated for the treatment of: - Vaginal candidiasis (vaginal yeast infections due to Candida ). - Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. - Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify
Fluconazole Tablets USP: Pink trapezoidal tablets containing 50, 100 or 200 mg of fluconazole USP are packaged in bottles. The 150 mg fluconazole tablets are pink, oval shaped, packaged in a blister card of 1 tablet. Fluconazole Tablets USP are supplied as follows: Fluconazole Tablets USP 50 mg: Engraved with “50” on one side and plain on the other side. NDC 68462-101-30 Bottles of 30 NDC 68462-101-10 Bottles of 1000 Fluconazole Tablets USP 100 mg: Engraved with “100” on one side and plain on the other side. NDC 68462-102-30 Bottles of 30 NDC 68462-102-10 Bottles of 1000 Fluconazole Tablets USP 150 mg: Engraved with “150” on one side and plain on the other side. NDC 68462-103-40 Carton of 12 blister cards of 1 tablet Fluconazole Tablets USP 200 mg: Engraved with “200” on one side and plain on the other side. NDC 68462-104-30 Bottles of 30 NDC 68462-104-10 Bottles of 1000
Abbreviated New Drug Application
FLUCONAZOLE - FLUCONAZOLE TABLET BLENHEIM PHARMACAL, INC. ---------- FLUCONAZOLE TABLETS USP RX ONLY DESCRIPTION Fluconazole USP, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration. Fluconazole USP is designated chemically as 2,4-difluoro-α,α -bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with an empirical formula of C H F N O and molecular weight 306.3. The structural formula is: Fluconazole USP is a white crystalline solid which is slightly soluble in water and saline. Fluconazole tablets USP contain 50, 100, 150, or 200 mg of fluconazole USP and the following inactive ingredients: croscarmellose sodium, dibasic calcium phosphate anhydrous, FD&C Red No. 40 aluminum lake dye, magnesium stearate, microcrystalline cellulose and povidone. CLINICAL PHARMACOLOGY PHARMACOKINETICS AND METABOLISM The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral routes. In normal volunteers, the bioavailability of orally administered fluconazole is over 90% compared with intravenous administration. Peak plasma concentrations (C ) in fasted normal volunteers occur between 1 and 2 hours with a terminal plasma elimination half-life of approximately 30 hours (range: 20 - 50 hours) after oral administration. In fasted normal volunteers, administration of a single oral 400 mg dose of fluconazole leads to a mean C of 6.72 μg/mL (range: 4.12 to 8.08 μg/mL) and after single oral doses of 50 - 400 mg, fluconazole plasma concentrations and AUC (area under the plasma concentration-time curve) are dose proportional. Administration of a single oral 150 mg tablet of fluconazole to ten lactating women resulted in a mean C of 2.61 μg/mL (range: 1.57 to 3.65 μg/mL). Steady-state concentrations are reached within 5 - 10 days following oral doses of 50 - 400 mg given once daily. Administration of a loading dose (on day 1) of twice the usual daily dose results in plasma 1 13 12 2 6 max max max concentrations close to steady-s read_full_document